Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib + Azacitidine vs Azacitidine in Newly Diagnosed AML With FLT3 Mutation
NCT02752035Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2016
- Primary completion
- Mar 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of gilteritinib in acute myeloid leukemia (AML) (4 cohorts), sponsored by Astellas Pharma. Primary endpoint: Overall Survival up to 79 months. Started Aug 2016; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02752035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752035.